S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K/AKT pathway

Sun, Y; Zhang, H; Meng, JP; Guo, F; Ren, DY; Wu, HS; Jin, X

Ren, DY; Wu, HS (通讯作者)，Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pancreat Surg, Wuhan, Peoples R China.;Ren, DY; Wu, HS (通讯作者)，Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Sino German Lab Personalized Med Pancreat Canc, Wuhan 430022, Peoples R China.;Jin, X (通讯作者)，Cent South Univ, Xiangya Hosp 2, Dept Urol, Changsha 410011, Hunan, Peoples R China.;Jin, X (通讯作者)，Cent South Univ, Uro Oncol Inst, Changsha 410011, Hunan, Peoples R China.

CELL REPORTS, 2022; 40 (7):

Abstract

Sorafenib is currently the first-line treatment for advanced hepatocellular carcinoma (HCC). However, sora-fenib resistance remains a significant chal......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索